On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).

The data will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition. Anito-cel is partnered with Kite, a Gilead Science Inc’s (NASDAQ:GILD) company.

Also Read: Arcellx’s Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson’s Multiple Myeloma Cell Therapies: Morgan Stanley

The Phase 2 iMMagine-1 data are from an October 31 data cutoff date, with a median follow-up of 9.5 months for the efficacy evaluable population.

At the time of the data cut, 86 patients were evaluable for efficacy based on a follow-up of at least two months after treatment with anito-cel, and 98 patients were evaluable for safety based on a follow-up of at least one month after treatment with anito-cel.

Preliminary results from the Phase 2 iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a high-risk fourth-line or higher RRMM population, including triple- and penta-class refractory disease.

The overall response rate (ORR) was 97% (83/86), with a complete response/stringent complete response (CR/sCR) rate of 62% (53/86) and a very good partial response or higher (>VGPR) rate of 81% (70/86).

Of those evaluable for minimal residual disease (MRD) testing, 93.1% (54/58) achieved MRD negativity at a minimum of 10-5 sensitivity.

Median progression-free survival (mPFS) and overall survival (OS) were not reached, with 6-month PFS and OS rates being 93.3% and 96.5%, respectively, and 12-month PFS and OS rates being 78.5% and 96.5%, respectively.

No delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome, have been observed to date in more than 150 patients dosed with anito-cel. 

Price Action: ACLX stock is up 6.46% at $90.01 during the premarket session at last check Monday.

Photo via Shutterstock.

Read Next:

• Blue Shield’s $500 Million Drug Savings Initiative With Amazon Pharmacy Can Potentially Launch In January

UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.

Get the latest stock analysis from Benzinga?

This article Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.